Elective Node Sparing in Head-and-Neck Cancer Radiotherapy Reduces Lymphocyte Damage, Lymphopenia, and Modulates Immune Signatures
This study demonstrates that elective node-sparing upfront boost strategies in head-and-neck cancer radiotherapy significantly reduce peripheral blood lymphocyte DNA damage and radiation-induced lymphopenia while promoting favorable immune signatures, thereby supporting their use to enhance radiotherapy-immunotherapy synergy.